Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Advance Cancer Treatment

Johnson & Johnson acquires Halda Therapeutics for $3.05B, gaining innovative prostate cancer treatment and platform technology for multiple solid tumors.